NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/09/2026
Back to search
Official data from USPTO
KALDENN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
KALDENN
ST13
US500000079403077Class
1, 5, 10
Filing
79403077
Registration
7885584
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
07/09/2026
Trademark type
Word
Nice classes
1, 5, 10
Filing date
05/14/2024
Registration date
08/12/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/12/2025
Last transaction
07/09/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
FR
Examiner
OAKES, JEFFREY ALLEN
Law office
O10
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
N. P. (pessoa física)
Representatives
Jeffrey H. Handelsman Greenblum & Bernstein, P.L.C.
Technical classification
Nice Classes
Class 1Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical substanceschemical materials and chemical products for use in medicine productionchemical additives and active chemical ingredients for use in the manufacture of radiopharmaceutical preparations and pharmaceuticals for detecting and treating coronary diseases and coronary artery diseases; chemical substanceschemical preparations and chemical products for use in radiopharmaceutical product manufacturechemical additives and active chemical ingredients for use in the manufacture of radiopharmaceutical preparations and pharmaceuticals for detecting and treating myocardial ischaemia; active chemical ingredients for use in manufacture of radiopharmaceutical preparations against cancer; diagnostic preparations for scientific use or for research; diagnostic reagents for scientific use or for research; radioactive preparations for laboratory use for scientific purposes; contrast agents for molecular imaging other than for medical use; rubidium; strontium
Class 5
Radiopharmaceutical productsradioactive substances for use in nuclear medicine; radioactive products for medical useradioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; radioactive substances for medical use; isotopes for medical use; radiopharmaceutical preparations for medical use made from radiopharmaceutical generatorsfor the detection and treatment of cancerscoronary diseasescoronary artery diseasesheart diseases and myocardial ischaemia; diagnostic radiopharmaceutical preparations; reagents and substances for medical diagnostic purposes; diagnostic biomarking reagents for medical use; contrast products being media for use with medical imaging equipment; cardiovascular medicines used in myocardial infarction treatment; contrast agents being media for use with molecular imaging equipment for medical use
Class 10
Radiopharmaceutical generators for medical use being medical generators specially adapted for medicaldiagnostic and therapeutic purposesnamely for use in the production and transportation of nuclear medicinesradioactive substances for medical purposesradiopharmaceutical products and radiopharmaceutical medicines; radioactive and radiopharmaceutical product generators for medical use being medical generators specially adapted for medical nuclear medicine purposesnamely for use in the production and transportation of nuclear medicinesradioactive substances for medical purposesradiopharmaceutical products and radiopharmaceutical medicines; rubidium-82 generators for medical use being medical generators specially adapted for medicaldiagnostic and therapeutic purposesnamely for use in the production and transportation of nuclear medicinesradioactive substances for medical purposesradiopharmaceutical products and radiopharmaceutical medicines; medication injectors for medical usemedical fluid injectors and injection devices for pharmaceuticals and radiopharmaceutical products; radiopharmaceutical medicine injectors being injection devices; radioactive and radiopharmaceutical product injectors for medical use being injection devices for pharmaceuticalsradioactive products and radiopharmaceutical products; automatic injectors being injection devices for administering radiopharmaceutical products; injectors of rubidium-82 to patients for medical usemedical fluid injectors and injection devices for pharmaceuticalsradioactive products and radiopharmaceutical products; magnetic resonance tomography apparatusmagnetic resonance imaging apparatus for medical purposes; medical equipmentcomputed tomography apparatus; tomographic scanners for nuclear medicineX-ray CT scanners; medical apparatus for diagnosing suspected heart attacks
Publications
History of USPTO decisions and trademark events.
33 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/26/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/19/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/21/2026
FIMP
FINAL DISPOSITION PROCESSED
02/21/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
02/12/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/27/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/27/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/12/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/12/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
08/12/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/24/2025
PUBO
PUBLISHED FOR OPPOSITION
06/24/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/18/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/21/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/15/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/15/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/15/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/15/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
05/15/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/15/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/15/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/15/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/15/2025
RFNT
REFUSAL PROCESSED BY IB
12/29/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/12/2024
RFRR
REFUSAL PROCESSED BY MPU
12/12/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/28/2024
CNRT
NON-FINAL ACTION WRITTEN
11/27/2024
DOCK
ASSIGNED TO EXAMINER
11/26/2024
MAFR
APPLICATION FILING RECEIPT MAILED
09/03/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/03/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/29/2024
Continuous trademark protection
Get notified about every new filing that threatens KALDENN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.